more

QIAGEN (QGEN)

(Real Time Quote from BATS)

$42.80 USD

-0.41 (-0.95%)

Updated Oct 17, 2024 12:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medtronic Receives FDA's Go Ahead for EFS Study on TTVR

by Zacks Equity Research Published on September 14,2020

Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.

medical

National Vision Banks on Contact Lens Sales Amid Coronavirus Woes

by Zacks Equity Research Published on September 14,2020

National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.

medical

Coronavirus Test Makers With Scope to Maximize Investor Benefits

by Urmimala Biswas Published on September 11,2020

The surge in new coronavirus infections broadens the scope for antigen and antibody tests.

medical

Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement

by Zacks Equity Research Published on September 11,2020

Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.

medical

Henry Schein Partners MouthWatch to Grow in Teledentistry

by Zacks Equity Research Published on September 10,2020

Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.

medical

QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test

by Zacks Equity Research Published on September 10,2020

QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.

BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research Published on September 10,2020

BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Henry Schein (HSIC) Enters Into New Dental Deal With Zyris

by Zacks Equity Research Published on September 08,2020

Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.

medical

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research Published on September 08,2020

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy

by Zacks Equity Research Published on September 07,2020

Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.

medical

Is QIAGEN N.V. (QGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on September 04,2020

Is (QGEN) Outperforming Other Medical Stocks This Year?

QGENNegative Net Change

Boston Scientific's Eluvia Gets CMS' Additional Reimbursement

by Zacks Equity Research Published on September 04,2020

Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.

medical

Why Is Qiagen (QGEN) Up 7.5% Since Last Earnings Report?

by Zacks Equity Research Published on September 03,2020

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QGENNegative Net Change

Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects

by Zacks Equity Research Published on September 03,2020

Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.

medical

Athenex's NDA for Breast Cancer Drug Gets Priority Review

by Zacks Equity Research Published on September 02,2020

The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.

biotechs

Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg

by Zacks Equity Research Published on September 02,2020

Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.

biotechs

Medtronic (MDT) Plans Up to $475M of Annual Cost Savings

by Zacks Equity Research Published on September 02,2020

Medtronic (MDT) expects its new operating model to help it become more focused in terms of speeding up research and developments.

medical

ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam

by Zacks Equity Research Published on September 02,2020

ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.

medical

Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up

by Zacks Equity Research Published on September 01,2020

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.